Literature DB >> 8563751

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

G Bollag1, D W Clapp, S Shih, F Adler, Y Y Zhang, P Thompson, B J Lange, M H Freedman, F McCormick, T Jacks, K Shannon.   

Abstract

Individuals with neurofibromatosis type 1 (NF1) are predisposed to certain cancers including juvenile chronic myelogenous leukaemia (JCML). The NF1 tumour-suppressor gene encodes a protein (neurofibromin) that accelerates GTP hydrolysis on Ras proteins. Here we show that primary leukaemic cells from children with NF1 show a selective decrease in NF1-like GTPase activating protein (GAP) activity for Ras but retain normal cellular GAP activity. Leukaemic cells also show an elevated percentage of Ras in the GTP-bound conformation. JCML cells are hypersensitive to granulocyte-macrophage colony stimulating factor (GM-CSF), and we observed a similar pattern of aberrant growth in haematopoietic cells from Nf1-/- mouse embryos. These data define a specific role for neurofibromin in negatively regulating GM-CSF signaling through Ras in haematopoietic cells and they suggest that hypersensitivity to GM-CSF may be a primary event in the development of JCML.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8563751     DOI: 10.1038/ng0296-144

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  160 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 2.  Vestibular schwannoma in a patient with neurofibromatosis type 1: clinical report and literature review.

Authors:  Aamira Huq; Maira Kentwell; Amanda Tirimacco; Jacqueline Rossini; Lesley Rawlings; Ingrid Winship
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

3.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

Review 4.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

5.  Molecular basis and clonal evolution of myeloproliferative neoplasms.

Authors:  Roland Jäger; Robert Kralovics
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

Review 6.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

7.  Neurofibromin is the major ras inactivator in dendritic spines.

Authors:  Ana F Oliveira; Ryohei Yasuda
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

8.  Biochemical and functional characterization of germ line KRAS mutations.

Authors:  Suzanne Schubbert; Gideon Bollag; Natalya Lyubynska; Hoa Nguyen; Christian P Kratz; Martin Zenker; Charlotte M Niemeyer; Anders Molven; Kevin Shannon
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

9.  Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Authors:  Steven D Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl W Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S Mohammad; Theresa A Guise; Mingjiang Xu; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

10.  Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.

Authors:  Xiaodong Zhou; Sung-Hoon Kim; Ling Shen; Hyo-Jung Lee; Changyan Chen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.